A Phase 3 interventional study of Ibrutinib and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Janssen Research & Development, LLC. Terminated at 77 sites in 20 countries. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2022-12-02.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. ibrutinib · Lymphoma, Non-Hodgkin.
Among the 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 9th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin are open now, in 12 countries. Recruiting first, the newest first:
Canadian Cancer Trials Group · Sites in Canada
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Janssen Research & Development, LLC · Sites in Australia, Belgium, Denmark and 12 more countries
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 1 Year to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 4 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 72 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson: 2 open now, 7 under way, none of them phase 3. Of 10 finished, 1 (10%) have results posted.
Among the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2016, is the only one in phase 3, and was the 4th registered.
Johnson & Johnson’s Lymphoma, Non-Hodgkin studies by the year they started, since 2005.
2 of the studies testing ibrutinib in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03229200Pharmacyclics Switzerland GmbHExtended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2027-05-10 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing ibrutinib in Lymphoma, Non-Hodgkin, from their registry updates:
Among Johnson & Johnson’s 17 in Lymphoma, Non-Hodgkin:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).
This is a Phase 3, randomized (study medication assigned to participants by chance), open-label (identity of study drug will be known to participant and study staff), controlled study which consists of two parts: Part 1 and Part 2. The Part 1 is a pharmacokinetic run-in part, which will be conducted before starting the randomized part (Part 2) of the study and Part 2 is a randomized and open-label study. Part 1 and Part 2 of the study will be conducted in 3 phases: a Pretreatment (Screening) Phase (Up to 14 days before administration of study drug), a Treatment Phase, and a Posttreatment Phase. The Treatment Phase will extend from enrollment (in Part 1) or randomization (in Part 2) until 1 of the following: 1) completion of 3 cycles of therapy, 2) transplantation, if clinically indicated, or 3) progressive disease (PD), whichever comes first. The Posttreatment Phase will continue until death, loss to follow up, consent withdrawal, or study end, whichever occurs first. The end of study is defined as when approximately 60 event-free survival (EFS) events have occurred in Part 2 (death, disease progression, or lack of complete response [CR] or partial response [PR] after 3 cycles of treatment based on blinded independent event review), or the sponsor terminates the study, whichever comes first. Participants in Part 1 will be 1 to less than (\<) 18 years old. Participants in Part 2 will be 1 to 30 years old. Participants will be primarily evaluated for pharmacokinetics in part 1 and efficacy (EFS) of ibrutinib in combination with RICE or RVICI background therapy compared to RICE or RVICI background therapy alone in part 2. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m\^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m\^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
Drug: Ibrutinib · Drug: Rituximab · Drug: Ifosfamide · Drug: Carboplatin · Drug: Etoposide · Drug: Vincristine · Drug: Idarubicin · Drug: Dexamethasone
Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
Drug: Ibrutinib · Drug: Rituximab · Drug: Ifosfamide · Drug: Carboplatin · Drug: Etoposide · Drug: Vincristine · Drug: Idarubicin · Drug: Dexamethasone
Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.
Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.
Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
AUC is defined as area under the plasma concentration-time curve. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 milligrams per meter square \[mg/m\^2\], 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Relationship Between AUC and Body Size
The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling.
Time frame: Up to Cycle 3 (each cycle of 28 days)
Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups
EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the Independent Review Committee (IRC). CR was defined as computed tomography (CT) or magnetic resonance imaging (MRI) reveals no residual disease or new lesions, resected residual mass that was pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50 percent (%) decrease in sum of the products of the lesion diameters (SPD) on CT or MRI; fluorodeoxyglucose (FDG)-positron emission tomography (PET) may be positive, no new or progressive disease (PD); morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
Time frame: Time from Randomization to death, disease progression, or lack of CR or PR after 3 cycles of treatment (up to 4 year and 4 months)
Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: Up to 4 year and 4 months
Part 1 and Part 2: Overall Response Rate (ORR)
ORR was defined as the percentage of participants achieving a best overall response of either complete response (CR) (including CR biopsy-negative \[CRb\] and unconfirmed CR \[CRu\]) or partial response (PR) as evaluated by International Pediatric non-Hodgkin lymphoma (NHL) response criteria. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; bone marrow (BM) and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
Time frame: Up to 4 year and 4 months
Part 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline
Tumor formalin-fixed paraffin-embedded (FFPE) samples were taken to evaluate the baseline gene expression by disease-specific biomarkers such as BCL-2L1 (BCL-xl), BIRC2 (cIAP1), Caspase 3 (CASP3), STAT3, and SYK. Transcripts per million (TPM) is a normalization method for RNA-sequencing, which means "for every 1,000,000 RNA molecules in the RNA-sequencing tumor FFPE sample, x came from this gene/transcript.
Time frame: Baseline
Part 1 and Part 2: Number of Participants With Immunoglobulin and T-cell Receptor Gene Rearrangements
Number of participants with immunoglobulin and T-cell receptor gene rearrangements were reported.
Time frame: At baseline (Cycle 1 Day 1) of Part 1 and 2
Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy
Number of participants with \>90% BTK occupancy were reported. Blood samples were collected to assess BTK occupancy.
Time frame: Up to 3 months
Part 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability
Palatability of ibrutinib was measured by using a VAS. The scale is a 5-point visual analog scale incorporating a facial hedonic scale designed to span pediatric ages and levels of participant comprehension with a score range of 1 to 5, where 1 represents best score and 5 is worst palatability.
Time frame: Day 1 of Cycle 1 and Cycle 3
Part 1: Number of Participants With CD79B, CARD11, and MYD Mutations
Number of Participants with CD79B, CARD11, and MYD Mutations were reported.
Time frame: Up to 4 years and 4 months
Part 2: Number of Participants With CD79B, CARD11, and MYD Mutations
Number of participants with CD79B, CARD11, and MYD mutations were reported. Blood samples were taken to evaluate the levels of biomarkers such as CD79B, CARD11, and MYD mutations.
Time frame: Up to 4 year and 4 months
Part 1: Number of Participants With c-MYC Gene Rearrangement
Number of participants with c-MYC gene rearrangement were reported.
Time frame: At baseline (Cycle 1 Day 1)
Part 2: Number of Participants With c-MYC Gene Rearrangement
Number of participants with c-MYC gene rearrangement were reported. Blood samples were taken to evaluate the levels of biomarker such as c-MYC Gene rearrangement.
Time frame: At baseline (Cycle 1 Day 1)
Part 2: Percentage of Participants Who Achieved Complete Response (CR)
Complete response rate was defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment.
Time frame: Up to 4 year and 4 months
Part 2: Percentage of Participants Who Achieved Partial Response (PR)
Percentage of participants who achieved PR were assessed. PR was defined as 50% decrease in SPD on computed tomography (CT) or magnetic resonance imaging (MRI); FDG-PET may be positive; no new or PD; morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
Time frame: Up to 4 year and 4 months
Part 2: Tumor Volume Reduction Rate at Day 14
The tumor volume reduction rate was defined as percent decrease in the sum of the products of the lesion diameters at Day 14. It was measured as the mean change in the sum of the products of the lesion diameters (SPD) at Day 14.
Time frame: At Day 14
Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation
Number of participants who proceeded to stem cell transplantation were reported.
Time frame: Up to end of the study (Up to 4 year and 4 months)
Part 2: Time to Response
Time to response was defined as the time interval from the first dose of ibrutinib to the first documented response for those participants who responded. Time to response was summarized for participants who achieved either CR (including CRb and CRu) or PR. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
Time frame: Up to 4 Years and 4 months
Part 2: Duration of Response
Duration of response was defined as the duration from date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death, whichever occurred first. PD: \>25% increase in SPD of residual lesions (calculated from nadir) on CT or MRI; Deauville score 4 or 5 on FDG-PET with increase in lesional uptake from baseline; documentation of new lesions or development of new morphologic evidence of disease in BM or CSF.
Time frame: Up to 4 year and 4 months
Part 2: Percentage of Participants With EFS at 2 Years
EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
Time frame: At 2 years
Part 2: Percentage of Participants With EFS at 3 Years
EFS is the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurs first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
Time frame: At 3 years
Part 2: Overall Survival
Overall survival was defined as duration from the date of randomization to the date of the participant's death.
Time frame: Up to 4 year and 4 months
Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
Time frame: Up to Cycle 3 (each cycle of 21 or 28 days)
Part 2: Relationship Between AUC and Body Size
The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling. This outcome measure was planned to be analyzed for specified arm only.
Time frame: Up to Cycle 3 (each cycle of 28 days)
| Milestone | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|---|---|
| Started | 11 | 10 | 35 | 16 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 11 | 10 | 35 | 16 |
| Withdrew: Death | 4 | 9 | 19 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 2 |
| Withdrew: Study terminated by sponsor | 6 | 1 | 12 | 4 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
AUC is defined as area under the plasma concentration-time curve. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 milligrams per meter square \[mg/m\^2\], 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| hours*nanogram per milliliter (h*ng/mL) | Part 1: Ibrutinib: 240 mg/m^2 | Part 1: Ibrutinib: 329 mg/m^2 | Part 1: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | 143 (116 to 170) | 386 (386 to 386) | 310 (230 to 543) |
| 6-11 years | 145 (140 to 233) | 349 (238 to 562) | 324 (185 to 538) |
| 12-17 years | 1210 (939 to 1450) | 661 (394 to 778) | — |
CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| milliliter per hour (mL/h) | Part 1: Ibrutinib: 240 mg/m^2 | Part 1: Ibrutinib: 329 mg/m^2 | Part 1: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | 1220 (1000 to 1430) | 508 (508 to 508) | 1200 (838 to 1550) |
| 6-11 years | 1450 (1080 to 1500) | 805 (664 to 1100) | 1300 (910 to 2460) |
| 12-17 years | 348 (340 to 433) | 729 (568 to 1330) | — |
Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| liter(s) | Part 1: Ibrutinib: 240 mg/m^2 | Part 1: Ibrutinib: 329 mg/m^2 | Part 1: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | 11.1 (8.26 to 13.9) | 5.18 (5.18 to 5.18) | 7.63 (5.34 to 11.1) |
| 6-11 years | 18 (10.8 to 29.9) | 7.55 (2.89 to 15.6) | 19 (6.09 to 55.9) |
| 12-17 years | 3.63 (2.32 to 4.77) | 11.3 (6.34 to 18.5) | — |
Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| nanograms per milliliter (ng/mL) | Part 1: Ibrutinib: 240 mg/m^2 | Part 1: Ibrutinib: 329 mg/m^2 | Part 1: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | 3.86 (3.75 to 3.98) | 4.48 (4.48 to 4.48) | 5.07 (4.5 to 5.14) |
| 6-11 years | 3.46 (3.12 to 3.6) | 3.64 (3.32 to 4.59) | 3.88 (3.2 to 4.44) |
| 12-17 years | 4.88 (4.76 to 5.4) | 4.73 (4.07 to 5.07) | — |
The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling.
No measurements were reported for this outcome.
EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the Independent Review Committee (IRC). CR was defined as computed tomography (CT) or magnetic resonance imaging (MRI) reveals no residual disease or new lesions, resected residual mass that was pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50 percent (%) decrease in sum of the products of the lesion diameters (SPD) on CT or MRI; fluorodeoxyglucose (FDG)-positron emission tomography (PET) may be positive, no new or progressive disease (PD); morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
| Months | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups | 6.05 (2.99 to 8.84) | 6.97 (2.60 to 11.07) |
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
| Participants | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|---|---|
| Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability | 11 | 10 | 35 | 15 |
ORR was defined as the percentage of participants achieving a best overall response of either complete response (CR) (including CR biopsy-negative \[CRb\] and unconfirmed CR \[CRu\]) or partial response (PR) as evaluated by International Pediatric non-Hodgkin lymphoma (NHL) response criteria. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; bone marrow (BM) and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
| Percentage of participants | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|---|---|
| Part 1 and Part 2: Overall Response Rate (ORR) | 81.8 | 50.0 | 68.6 | 81.3 |
Tumor formalin-fixed paraffin-embedded (FFPE) samples were taken to evaluate the baseline gene expression by disease-specific biomarkers such as BCL-2L1 (BCL-xl), BIRC2 (cIAP1), Caspase 3 (CASP3), STAT3, and SYK. Transcripts per million (TPM) is a normalization method for RNA-sequencing, which means "for every 1,000,000 RNA molecules in the RNA-sequencing tumor FFPE sample, x came from this gene/transcript.
| Transcripts per million | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|---|---|
| BCL-2L1 (BCL-xl) | — | — | 58.09346 ± 38.75996 | 74.30790 ± 75.82331 |
| BIRC2 (cIAP1) | — | — | 47.20787 ± 16.26430 | 40.01716 ± 9.28104 |
| Caspase 3 (CASP3) | — | — | 51.14711 ± 21.44109 | 47.61412 ± 32.12666 |
| STAT3 | — | — | 540.02256 ± 363.75256 | 526.35308 ± 473.08255 |
| SYK | — | — | 705.29909 ± 503.07085 | 618.36324 ± 144.72067 |
Number of participants with immunoglobulin and T-cell receptor gene rearrangements were reported.
No measurements were reported for this outcome.
Number of participants with \>90% BTK occupancy were reported. Blood samples were collected to assess BTK occupancy.
| Participants | Part 1: Ibrutinib | Part 2: Ibrutinib |
|---|---|---|
| Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy | 5 | 5 |
Palatability of ibrutinib was measured by using a VAS. The scale is a 5-point visual analog scale incorporating a facial hedonic scale designed to span pediatric ages and levels of participant comprehension with a score range of 1 to 5, where 1 represents best score and 5 is worst palatability.
| Units on a scale | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) |
|---|---|---|---|
| Cycle 1 Day 1 | 2.6 ± 1.21 | 3.2 ± 1.40 | 2.4 ± 1.16 |
| Cycle 3 Day 1 | 3.3 ± 1.39 | 2.3 ± 1.15 | 2.6 ± 0.89 |
Number of Participants with CD79B, CARD11, and MYD Mutations were reported.
No measurements were reported for this outcome.
Number of participants with CD79B, CARD11, and MYD mutations were reported. Blood samples were taken to evaluate the levels of biomarkers such as CD79B, CARD11, and MYD mutations.
| Participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| CD79B | 1 | 0 |
| CARD11 | 1 | 0 |
| MYD mutation | 0 | 0 |
Number of participants with c-MYC gene rearrangement were reported.
No measurements were reported for this outcome.
Number of participants with c-MYC gene rearrangement were reported. Blood samples were taken to evaluate the levels of biomarker such as c-MYC Gene rearrangement.
| Participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Number of Participants With c-MYC Gene Rearrangement | 1 | 1 |
Complete response rate was defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment.
| Percentage of Participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Percentage of Participants Who Achieved Complete Response (CR) | 17.1 | 18.8 |
Percentage of participants who achieved PR were assessed. PR was defined as 50% decrease in SPD on computed tomography (CT) or magnetic resonance imaging (MRI); FDG-PET may be positive; no new or PD; morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
| percentage of participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Percentage of Participants Who Achieved Partial Response (PR) | 51.4 | 62.5 |
The tumor volume reduction rate was defined as percent decrease in the sum of the products of the lesion diameters at Day 14. It was measured as the mean change in the sum of the products of the lesion diameters (SPD) at Day 14.
| Percent change | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Tumor Volume Reduction Rate at Day 14 | -49.7 ± 33.41 | -58.60 ± 34.04 |
Number of participants who proceeded to stem cell transplantation were reported.
| Participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation | 13 | 7 |
Time to response was defined as the time interval from the first dose of ibrutinib to the first documented response for those participants who responded. Time to response was summarized for participants who achieved either CR (including CRb and CRu) or PR. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
| Months | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Time to Response | 0.89 (0.49 to 1.87) | 0.82 (0.46 to 1.94) |
Duration of response was defined as the duration from date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death, whichever occurred first. PD: \>25% increase in SPD of residual lesions (calculated from nadir) on CT or MRI; Deauville score 4 or 5 on FDG-PET with increase in lesional uptake from baseline; documentation of new lesions or development of new morphologic evidence of disease in BM or CSF.
| Months | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Duration of Response | 6.01 (3.06 to NA) | 6.51 (4.53 to 10.64) |
EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
| Percentage of participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Percentage of Participants With EFS at 2 Years | 14.3 | 12.5 |
EFS is the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurs first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells.
| Percentage of participants | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Percentage of Participants With EFS at 3 Years | 8.6 | 12.5 |
Overall survival was defined as duration from the date of randomization to the date of the participant's death.
| Months | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|
| Part 2: Overall Survival | 14.13 (5.98 to NA) | 11.07 (7.39 to NA) |
AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| h*ng/mL | Part 2: Ibrutinib: 240 mg/m^2: | Part 2: Ibrutinib: 329 mg/m^2 | Part 2: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | — | — | 298 (268 to 327) |
| 6-11 years | — | — | 655 (428 to 879) |
| 12-17 years | 215 (215 to 215) | 499 (262 to 887) | — |
| 18+ years | — | 423 (348 to 498) | — |
CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| mL/h | Part 2: Ibrutinib: 240 mg/m^2 | Part 2: Ibrutinib: 329 mg/m^2 | Part 2: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | — | — | 1110 (1020 to 1200) |
| 6-11 years | — | — | 856 (618 to 1140) |
| 12-17 years | 1730 (1730 to 1730) | 982 (598 to 2010) | — |
| 18+ years | — | 1510 (1250 to 1780) | — |
Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| liter(s) | Part 2: Ibrutinib: 240 mg/m^2 | Part 2: Ibrutinib: 329 mg/m^2 | Part 2: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | — | — | 1.68 (1.46 to 1.91) |
| 6-11 years | — | — | 6.18 (3.67 to 10.01) |
| 12-17 years | 9.9 (9.9 to 9.9) | 4.14 (1.46 to 8.51) | — |
| 18+ years | — | 9.29 (7.75 to 10.8) | — |
Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age group (1-5, 6-11, 12-17 and \>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.
| ng/mL | Part 2: Ibrutinib: 240 mg/m^2 | Part 2: Ibrutinib: 329 mg/m^2 | Part 2: Ibrutinib: 440 mg/m^2 |
|---|---|---|---|
| 1-5 years | — | — | 3.79 (3.52 to 4.06) |
| 6-11 years | — | — | 4.15 (3.44 to 5.01) |
| 12-17 years | 2.93 (2.93 to 2.93) | 4.86 (3.12 to 5.26) | — |
| 18+ years | — | 3.7 (3.46 to 3.94) | — |
The relationship between ibrutinib metrics of systemic exposure (AUC) with body size was assessed to determine the impact on AUC which were presented per dose groups (240 mg/m\^2, 329 mg/m\^2 and 440 mg/m\^2) and age groups (1-5, 6-11, 12-17 and \>18 years). The data could not be analyzed in tabular format for this outcome measure as they correspond to a flat regression line in nonlinear mixed effects modeling. This outcome measure was planned to be analyzed for specified arm only.
No measurements were reported for this outcome.
Collected over Up to 4 year and 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Ibrutinib+RICE | 4/11 (36.4%) | 10/11 (90.9%) | 11/11 (100%) |
| Part 1: Ibrutinib+RVICI | 9/10 (90%) | 9/10 (90%) | 10/10 (100%) |
| Part 2: Ibrutinib+CIT (RICE or RVICI) | 19/35 (54.3%) | 25/35 (71.4%) | 35/35 (100%) |
| Part 2: Chemoimmunotherapy | 10/15 (66.7%) | 11/15 (73.3%) | 15/15 (100%) |
| Event | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/11 | 3/10 | 21/35 | 6/15 |
| SepsisInfections and infestations | 1/11 | 4/10 | 5/35 | 3/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/11 | 0/10 | 3/35 | 4/15 |
| AnaemiaBlood and lymphatic system disorders | 0/11 | 0/10 | 2/35 | 3/15 |
| LeukopeniaBlood and lymphatic system disorders | 0/11 | 0/10 | 0/35 | 3/15 |
| NeutropeniaBlood and lymphatic system disorders | 2/11 | 1/10 | 2/35 | 3/15 |
| Escherichia SepsisInfections and infestations | 0/11 | 0/10 | 1/35 | 2/15 |
| Sinus TachycardiaCardiac disorders | 0/11 | 1/10 | 0/35 | 0/15 |
| ColitisGastrointestinal disorders | 0/11 | 1/10 | 1/35 | 1/15 |
| DiarrhoeaGastrointestinal disorders | 0/11 | 1/10 | 0/35 | 0/15 |
| Event | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 8/11 | 9/10 | 29/35 | 14/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/11 | 8/10 | 19/35 | 4/15 |
| VomitingGastrointestinal disorders | 5/11 | 5/10 | 25/35 | 4/15 |
| NauseaGastrointestinal disorders | 7/11 | 5/10 | 21/35 | 2/15 |
| NeutropeniaBlood and lymphatic system disorders | 6/11 | 6/10 | 14/35 | 4/15 |
| DiarrhoeaGastrointestinal disorders | 4/11 | 6/10 | 10/35 | 3/15 |
| Neutrophil Count DecreasedInvestigations | 1/11 | 2/10 | 12/35 | 9/15 |
| HypokalaemiaMetabolism and nutrition disorders | 2/11 | 6/10 | 12/35 | 6/15 |
| Platelet Count DecreasedInvestigations | 5/11 | 2/10 | 12/35 | 8/15 |
| Abdominal PainGastrointestinal disorders | 3/11 | 5/10 | 12/35 | 2/15 |
| Age, Continuous(years) | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy | Total |
|---|---|---|---|---|---|
| Mean | 10.5 ± 4.91 | 8.3 ± 3.43 | 13.9 ± 3.94 | 13.2 ± 4.37 | 12.4 ± 4.54 |
| Sex: Female, Male(Participants) | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 12 | 3 | 19 |
| Male | 8 | 9 | 23 | 13 | 53 |
| Race/Ethnicity, Customized(Participants) | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 8 | 6 | 15 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 9 | 10 | 22 | 8 | 49 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 3 | 0 | 4 |
| Other | 0 | 0 | 2 | 1 | 3 |
| Region of Enrollment(Participants) | Part 1: Ibrutinib+RICE | Part 1: Ibrutinib+RVICI | Part 2: Ibrutinib+CIT (RICE or RVICI) | Part 2: Chemoimmunotherapy | Total |
|---|---|---|---|---|---|
| BELGIUM | 0 | 0 | 2 | 0 | 2 |
| BRAZIL | 1 | 0 | 1 | 2 | 4 |
| BULGARIA | 0 | 0 | 2 | 0 | 2 |
| CANADA | 0 | 0 | 1 | 0 | 1 |
| CZECH REPUBLIC | 0 | 2 | 2 | 0 | 4 |
| FRANCE | 2 | 1 | 3 | 1 | 7 |
| GERMANY | 2 | 1 | 3 | 0 | 6 |
| ITALY | 2 | 1 | 4 | 2 | 9 |
| NETHERLANDS | 0 | 0 | 1 | 1 | 2 |
| POLAND | 0 | 1 | 0 | 2 | 3 |
| ROMANIA | 1 | 0 | 0 | 0 | 1 |
| RUSSIAN FEDERATION | 0 | 0 | 2 | 0 | 2 |
| SOUTH KOREA | 1 | 0 | 5 | 4 | 10 |
| SPAIN | 0 | 0 | 2 | 0 | 2 |
| SWEDEN | 0 | 0 | 1 | 0 | 1 |
| TAIWAN | 0 | 0 | 2 | 1 | 3 |
| TURKEY | 1 | 4 | 1 | 2 | 8 |
| UKRAINE | 0 | 0 | 1 | 0 | 1 |
| UNITED KINGDOM | 0 | 0 | 1 | 1 | 2 |
| UNITED STATES | 1 | 0 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Jun 2021, 59 months.
Results were first posted in Dec 2022, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Janssen Research & Development, LLC →